E3 ubiquitin-protein ligase TRIP12 (TRIP12)

E3 ubiquitin-protein ligase TRIP12 (TRIP12) is a member of the HECT-type E3 ubiquitin ligase family, first identified as a thyroid hormone receptor interactor[5]. It plays a central role in ubiquitin-mediated proteolysis, targeting a diverse array of substrates such as p14/ARF, ASXL1, SOX6, BAF57, and BRG1, among others[1][4][5]. TRIP12 regulates critical processes including the cell cycle, mitotic entry, DNA replication, genome integrity, chromatin remodeling, Wnt/β-catenin signaling, epithelial-mesenchymal transition, and protein homeostasis[1][2][3]. TRIP12 expression and activity are tightly regulated and its dysfunction or altered expression is linked to cancer development, tumor progression, and metastasis[1][3][5]. High levels of TRIP12 have been correlated with poor prognosis in certain cancer types. Knockout or loss-of-function mutations in TRIP12 result in embryonic lethality in mice, underscoring its essential role in cellular homeostasis[5]. At present, there are no clinically approved drugs targeting TRIP12, but its enzymatic activity and diverse involvement in disease processes make it a candidate for therapeutic intervention.

Other names

Thyroid hormone receptor interactor 12KIAA0045ULFTR-interacting protein 12TRIP-12TRIPCE3 ubiquitin-protein ligase for ArfHECT-type E3 ubiquitin transferase TRIP12

Drugs targeting TRIP12 would be expected to modulate ubiquitin-mediated degradation of substrate proteins involved in cell cycle, DNA repair, or oncogenic signaling (no direct therapeutic drugs currently established)